Last reviewed · How we verify

NCT05734781

End-of-life Communication From a Chinese Perspective

Completed Last updated 4 November 2024
What this trial tests

trial testing Not Application as this is a qualitative study in Terminally Ill in 66 participants. Completed in 31 October 2023.

Timeline
4 May 2023
Primary endpoint
31 October 2023
31 October 2023

Quick facts

Lead sponsorThe Hong Kong Polytechnic University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment66
Start date4 May 2023
Primary completion31 October 2023
Estimated completion31 October 2023
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

The Hong Kong Polytechnic University

Who can join

18 and older, any sex, with Terminally Ill. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this observational study is to explore experiences and perceptions of end-of-life communication in Chinese terminally ill patients, families and healthcare providers. The main question it aims to answer is: • What are the experiences and perceptions of end-of-life communication in Chinese terminally ill patients, families and healthcare providers? Participants will be invited to either semi-structured in-depth interviews or focus group discussions to share their thoughts.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Patients', families' and healthcare providers' perspectives on end-of-life communication in Chinese hospital settings: A qualitative study protocol.
    Chen W, Chung JOK, Lam KKW, Molassiotis A. · · 2023 · cited 4× · PMID 38150444 · DOI 10.1371/journal.pone.0296342

Verify or expand the search:

Other trials of Not Application as this is a qualitative study

Trials testing the same drug.

Other The Hong Kong Polytechnic University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05734781.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing